10:31 AM EDT, 07/30/2025 (MT Newswires) -- Bioventus ( BVS ) said Wednesday that the US Food and Drug Administration has given 510(k) clearances for TalisMann and StimTrial, the company's peripheral nerve stimulation, or PNS, devices for chronic pain management.

TalisMann targets deeper, larger nerves and is designed to provide long-term relief from chronic nerve pain. StimTrial allows doctors to test how patients respond to PNS therapy before starting full treatment, the company said.

The company added that it expects to begin a limited US launch of the devices during the third quarter, with a wider release in early 2026.

Shares of Bioventus ( BVS ) rose over 5% in recent trading activity.

Price: 6.88, Change: +0.34, Percent Change: +5.20